Industries > Pharma > Antibody Drug Conjugates Market Report 2021-2031

Back to Pharma Reports

Antibody Drug Conjugates Market Report 2021-2031

Forecasts by Technology (Cleavable Linkers, Non-Cleavable Linkers, Other Technology), by Payload Type (MMAE, DM4, Camptothecin, DM1, MMAF, Other Payload Type), by Target Antigen (CD30, HER2, CD22, CD33), by Drug Type (Adcetris, Kadcyla, Other Drugs), by Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Application), by Linker Type (VC, VA, SMCC, Hydrazone, Other Linker Type). PLUS COVID-19 Impact Analysis and Recovery Pattern Analysis (V-shaped, W-shaped, U-shaped, L-shaped) AND Profiles of Leading Companies, Region and Country

PUBLISHED: 03 November 2020

PAGES: 498

PRODUCT CODE: PHA0556

SUBMARKET: Drug Discovery Development & Production

SKU: PHA0556 Categories: Drug Discovery Development & Production, Pharma Tags: PHA0556, PHA1133, PHA1203

Visiongain has estimated that the total market for Antibody Drug Conjugates would be around $xx billion in 2020 and is projected to grow at a CAGR of xx% during the forecast period 2021-2031. Shouldn’t you be part of this market?

Antibody drug conjugate (ADC) technology continues to evolve as a widely successful drug targeting technology for the treatment of cancer. Advances in targeting antibodies, potent payloads and drug-linker technologies that facilitate improved ADC stability, potency and targeting efficiency led to the development of ten commercially viable ADCs. Shouldn’t you be part of this innovative market?

Antibody Drug Conjugates Market – Our new market research study shows trends, developments, progress in R&D and forecast revenue till 2031. The study offers YOU an in-depth assessment of competitors journeys within the market and its segments.

This report tell you how to stay ahead
Almost 600 tables and graphs are included in our just 500-page report. Read about the most lucrative industries and the future prospects on the market. Our new study allows you to evaluate forecast sales worldwide and regional. See financial results, trends, opportunities and forecasts of revenue. In this growing Antibody Drug Conjugates market a lot of opportunity remains. See how opportunities can be taken advantage of.

What are the key factors to reshaping the growth of the Antibody Drug Conjugates market? You must read this new report immediately. This exclusive report by Visiongain shows you potential revenue opportunity pool until 2031 for the assessment of data, trends, opportunities and business outlooks.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

To access the data contained in this document please email contactus@visiongain.com

How Increased Research on ADC Development Will Help the Market to Grow?

ADC Industry Involves a Specialization Business Model – be part of its success.

Will Innovation in ADCs Disrupt the Market in Future?
• Use of known or approved antibodies and cytotoxins in ADCs means potentially streamlined reviews and briefer development cycles.
• Technological advances, including stable linker technologies, have provided the impetus to develop more targeted and efficacious ADCs.
• Development of more stable linkers and potent cytotoxins are likely to ensure that the next generation ADCs have an improved safety/efficacy profile.
• Increasing incidence of cancer is also contributing to the development of ADCs.

Is Complexity of ADCs hindering its Growth?
Manufacturing an ADC is a complex process. It requires a small molecule, an antibody, chemical linking chemistry and different amino acid conjugation. Antibody drug conjugates exhibit a more complex and heterogeneous structure than the parent monoclonal antibody. This complexity and heterogeneity present a significant challenge for generic manufacturers to copy the ADCs; thus, the complexity of ADCs preserves companies’ investment longer.

Forecasts to 2031 and other analyses reveal the commercial prospects of Antibody Drug Conjugates Market
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the Antibody Drug Conjugates market and submarkets

Global Antibody Drug Conjugates Market by Technology
Cleavable Linkers
Non-Cleavable Linkers
Other Technology
Global Antibody Drug Conjugates Market by Payload Type
MMAE
DM4
Camptothecin
DM1
MMAF
Other Payload Type

Global Antibody Drug Conjugates Market by Target Antigen
CD30
HER2
CD22
CD33

Global Antibody Drug Conjugates Market by Drug Type
Adcetris
Kadcyla
Other Drugs

Global Antibody Drug Conjugates Market by Application
Blood Cancer
Breast Cancer
Ovarian Cancer
Lung Cancer
Brain Tumor
Other Application

Global Antibody Drug Conjugates Market by Linker Type
VC
VA
SMCC
Hydrazone
Other Linker Type

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:

• North America Antibody Drug Conjugates Market Outlook
o U.S. Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o Canada Antibody Drug Conjugates Market Forecast & COVID Impact Analysis

• Europe Antibody Drug Conjugates Market Outlook
o Germany Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o France Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o United Kingdom Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o Italy Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o Russia Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o Rest of Europe Market Forecast & COVID Impact Analysis

• Asia Pacific Antibody Drug Conjugates Market Outlook
o China Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o Japan Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o India Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o Australia Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o South Korea Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o Rest of Asia Pacific Market Forecast & COVID Impact Analysis

• Latin America Antibody Drug Conjugates Market Outlook Market Forecast & COVID Impact Analysis
o Brazil Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o Mexico Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o Rest of Latin America Market Forecast & COVID Impact Analysis

• Middle East and Africa Antibody Drug Conjugates Market Outlook
o Saudi Arabia Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o South Africa Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o UAE Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o Rest of Middle East and Africa

Need industry data? Please contact us today.

The report also includes profiles and for some of the leading companies in the Antibody Drug Conjugates Market, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
AbbVie Inc.
Astellas Pharma Inc
Bayer Pharmaceuticals
Celldex Therapeutics, Inc.
Genentech Biotechnology
ImmunoGen Biotechnology
Immunomedics Inc
Lonza Group AG (Lonza)
Mersana Therapeutics Inc.
Takeda Pharmaceutical Company Limited
Roche Holding AG (Roche)
Pfizer Inc. (Pfizer)
Lantheus Holdings, Inc.
Seattle Genetics, Inc.
Merck KGaA

Overall world revenue for Antibody Drug Conjugates Market will surpass $xx billion in 2020, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

Key Questions Answered in the report
• What are the best investment options for venturing into new product and service lines?
• What value proposals should businesses aim at while providing new funding for research and development?
• Which regulations will be most useful for stakeholders to enhance their supply chain network?
• Which regions could see demand ripening in certain segments in the near future?
• What are some of the best cost optimization strategies with vendors that some well-trained players have been successful with?
• What are the key perspectives that C-suite is leveraging to move businesses to a new growth trajectory?
• Which government regulations could call into question the status of key regional markets?
• How will the emerging political and economic scenario affect opportunities in key areas of growth?
• What are some of the value-added opportunities in different segments?
• What will be the barriers to entry for new players on the market?

How the Antibody Drug Conjugates Market report helps you?
In summary, our 490+ page report provides you with the following knowledge:

• Revenue forecasts to 2031 for Antibody Drug Conjugates Market, with forecasts for Technology, Linker Type, Drug Type, Payload Type, Application each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2031 for 5 regional and 20 key national markets – See forecasts for the Antibody Drug Conjugates market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Russia, Germany, France, UK, Italy, China, India, Japan, Korea and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 15 of the major companies involved in the Antibody Drug Conjugates Market.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Antibody Drug Conjugates Market and leading companies. You will find data, trends and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Antibody Drug Conjugates Market Report 2021-2031: Forecasts by Technology (Cleavable Linkers, Non-Cleavable Linkers, Other Technology), by Payload Type (MMAE, DM4, Camptothecin, DM1, MMAF, Other Payload Type), by Target Antigen (CD30, HER2, CD22, CD33), by Drug Type (Adcetris, Kadcyla, Other Drugs), by Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Application), by Linker Type (VC, VA, SMCC, Hydrazone, Other Linker Type). PLUS COVID-19 Impact Analysis and Recovery Pattern Analysis (V-shaped, W-shaped, U-shaped, L-shaped) AND Profiles of Leading Companies, Region and Country. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

1 Report Overview

1.1 Global Antibody Drug Conjugate Market Overview

1.2 Visiongain Study Goals and Objectives

1.3 Why it is Important to Study This Market?

1.4 What is the Scope of this Report?

1.5 Market Definitions

1.5.1 Antibody

1.5.2 Antigen

1.5.3 Cytotoxicity

1.5.4 Endocytosis

1.5.5 Immune system

1.5.6 Hybridoma Technology

1.5.7 Antibody drug conjugates (ADCs)

1.6 Why You Should Read This Report

1.7 How This Report Delivers

1.8 Key Questions Answered by This Analytical Report Include:

1.9 Who is This Report for?

1.10 Methodology

1.10.1 Primary Research

1.10.2 Secondary Research

1.11 Market Segmentation

1.12 Frequently Asked Questions (FAQ)

1.13 Associated Visiongain Reports

2 Executive Summary

2.1 What are the Advantages of ADCs

3 Antibody Drug Conjugate Technology Background

3.1 Overview

3.2 The Action Mechanism of ADC

3.3 Components of ADCs

3.4 How ADCs Work?

3.5 Antibody Drug Conjugation Technologies

3.5.1 How Good are Cysteine Conjugation?

3.5.2 Conjugation Methods Overview

3.5.3 Cysteine-Based Conjugation

3.5.4 Lysine-Based Conjugation

3.5.5 Site-Specific Conjugation

3.6 Types of Monoclonal Antibodies

4 What is the Current Status of ADCs Market?

4.1 FDA Approved Antibody Drug Conjugates

4.2 ADCs for Clinical Research in the Global Market

4.3 Innovative Linker Technology for Antibody Drug Conjugates (ADCs)

4.4 SWOT Analysis of Antibody Drug Conjugates Market

4.4.1 Strengths of ADC Market

4.4.1.1 The unique targeting capabilities and promising clinical trial results

4.4.1.2 Advances in targeting antibodies, potent payloads and drug-linker technologies

4.4.1.3 The growing number of cancer patients and increasing demand for biologics for the treatment

4.4.2 Weaknesses of ADC Market

4.4.2.1 dose-limiting toxicities such as liver toxicity or neutropenia

4.4.2.2 disulfide-based linkers suffer from premature loss of payload cargo

4.4.2.3 leading to less drug delivered to the tumor and more toxicity

4.4.3 Opportunities in the ADC Market

4.4.3.1 an innovative class of drugs that are mainly developed by conjugating already

4.4.3.2 have the potential to replace conventional treatment options

4.4.3.3 Most pharmaceutical companies are investing in the ADC industry

4.4.4 Threats in the ADC Market

4.4.4.1 The development of any drug is no simple matter, and it is even more complex for ADCs

4.4.4.2 ADC mechanistic pathway consists of a complicated sequence of events

4.4.4.3 Pathway complexity is the main reason so many previous attempts have been unsuccessful

4.5 Porter’s Five Forces Analysis

4.5.1 Threat of New Entrants (High)

4.5.2 Rivalry Among the Existing Players (Low)

4.5.3 Bargaining Power of Suppliers (High)

4.5.4 Threats from Substitute Products (Moderate to High)

4.5.5 Bargaining Power of Buyers (Low)

5 Which Factors Are Driving or Restraining the Growth of the Market?

5.1 Which are Market Driving Forces?

5.1.1 Is Patent Expiration a Master Key to Enter Global Market?

5.1.2 Targeted Nature of ADCs is Promising

5.1.3 How Increased Research on ADC Development Will Help the Market to Grow?

5.1.4 How Technological Advancements Are Driving Growth?

5.1.5 ADC Industry Involves a Specialization Business Model

5.1.6 Will Innovation in ADCs Disrupt the Market in Future?

5.1.7 Other Factors Boosting the Market Growth

5.2 Which Barriers Are Restraining the Market Growth?

5.2.1 Is Complexity of ADCs hindering its Growth?

5.2.2 Which are the Regulatory Issues Associated with ADC Products?

5.2.3 Regulatory Exclusivity

5.2.4 Which Challenges Companies have to Face in the Global Market?

5.3 What are the Opportunities in the Global Market?

5.3.1 Growth in Number of Cancer Patients in the World

5.3.2 Increasing Cost of Cancer Treatment

6 Global Market Outlook (COVID Impact Recovery Analysis)

6.1 How Much Worth is the Global Antibody Drug Conjugate Market?

6.2 Which Region is Leading the Antibody Drug Conjugate Market?

6.3 Global ADC Market Analysis by Technology

6.3.1 Is Cleavable Linkers Really in Demand?

6.3.2 Type of Linkers

6.4 Global ADC Market Analysis by Payload Type

6.4.1 Why MMAE Payload is Gaining More Traction than Others?

6.4.2 Types of Payloads (Cytotoxic Agents)

6.4.3 MMAE

6.4.4 DM4

6.4.5 Camptothecin

6.4.6 DM1

6.4.7 MMAF

6.5 Global ADC Market Analysis by Target Antigen

6.5.1 CD19

6.5.2 CD20

6.5.3 CD22

6.5.4 CD25

6.5.5 CD30

6.5.6 CD33

6.5.7 CD40

6.5.8 CD56

6.5.9 CD74

6.5.10 CD79a and CD79b

6.5.11 CD138 (Syndecan-1)

6.5.12 CEACAM (Carcinoembryonic Antigen-Related Cell Adhesion Molecule)

6.5.13 EGFR (Epidermal Growth Factor Receptor/ERBB1)

6.5.14 EGP-1 (Epithelial Glycoprotein-1 Antigen)

6.5.15 GPNMB

6.5.16 LIV-1

6.5.17 Mesothelin

6.5.18 Nectin-4

6.5.19 Prostate-Specific Membrane Antigen (PSMA)

6.5.20 SLITRK6

6.5.21 VEGF (Vascular Endothelial Growth Factor)

6.5.22 HER2 Targeting ADCs

6.6 Global ADC Market Analysis by Drug Type

6.6.1 Adcetris

6.6.2 Kadcyla

6.7 Global Antibody Drug Conjugates Market Analysis by Linker Type

6.7.1 Valine-Citrulline (VC)

6.7.2 Sulfo-SPDB

6.7.3 SMCC

6.7.4 VA

6.7.5 Hydrazone

6.8 Which Application is Driving More Demand for Antibody Drug Conjugate Market?

6.8.1 ADC Application Overview

6.8.2 Breast Cancer

6.8.3 Lymphoma

6.8.4 Other Types of Cancer

7 North America Market Outlook (COVID Impact Recovery Analysis)

7.1 How North America is Dominating the Global Antibody Drug Conjugate Market?

7.2 North America Antibody Drug Conjugates Market by Country

7.3 US Antibody Drug Conjugate Market Outlook

7.4 Canada Antibody Drug Conjugate Market Outlook

7.5 North America Antibody Drug Conjugates Market by Technology

7.6 North America Antibody Drug Conjugates Market by Payload Type

7.7 North America Antibody Drug Conjugates Market by Target Antigen

7.8 North America Antibody Drug Conjugates Market by Drug

7.9 North America Antibody Drug Conjugates Market Analysis by Linker Type

7.10 North America Antibody Drug Conjugates Market by Application

8 Europe Market Outlook (COVID Impact Recovery Analysis)

8.1 How Much Worth is the Antibody Drug Conjugate Market in Europe?

8.2 Europe Antibody Drug Conjugates Market by Country

8.3 How Russia ADC Market is Performing?

8.4 What is the Status of Germany Market?

8.5 How Much Value Does UK ADC Market Holds?

8.6 How Much to Expect from France ADC Market?

8.7 What is the Growth Rate of Italy ADC Market?

8.8 Rest of Europe ADC Market Outlook

8.9 Europe Antibody Drug Conjugates Market by Technology

8.10 Europe Antibody Drug Conjugates Market by Payload Type

8.11 Europe Antibody Drug Conjugates Market by Target Antigen

8.12 Europe Antibody Drug Conjugates Market by Drug

8.13 Europe Antibody Drug Conjugates Market by Linker Type

8.14 Europe Antibody Drug Conjugates Market by Application

9 Asia-Pacific Market Outlook (COVID Impact Recovery Analysis)

9.1 How Big is the Asia-Pacific Market in Terms of Value?

9.2 Is Japan Really Leading the Antibody Drug Conjugate Market in the Region?

9.3 Why Japan is Holding Strong Position in the Region?

9.4 How Big is the China ADC Market?

9.5 Why ADC Market in India is Growing at Faster Rate?

9.6 How South Korea Market is Performing?

9.7 Is Australia ADC Market Worth Investing?

9.8 Rest of Asia-Pacific ACD Market Outlook

9.9 Asia-Pacific Antibody Drug Conjugates Market by Technology

9.10 Asia-Pacific Antibody Drug Conjugates Market by Payload Type

9.11 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen

9.12 Asia-Pacific Antibody Drug Conjugates Market by Drug

9.13 Asia-Pacific Antibody Drug Conjugates Market by Linker Type

9.14 Asia-Pacific Antibody Drug Conjugates Market by Application

10 LAMEA Market Outlook (COVID Impact Recovery Analysis)

10.1 What is the Status of Antibody Drug Conjugate Market in the Region?

10.2 LAMEA Antibody Drug Conjugates Market by Country

10.3 Is Brazil Leading ADC Market in the LAMEA Region?

10.4 How Much Worth is Saudi Arabia ADC Market?

10.5 Are there Any Opportunities in the South Africa ADC Market?

10.6 How Mexico ADC Market is Performing?

10.7 UAE ADC Market Outlook

10.8 Rest of LAMEA Market Outlook

10.9 LAMEA Antibody Drug Conjugates Market by Technology

10.10 LAMEA Antibody Drug Conjugates Market by Payload Type

10.11 LAMEA Antibody Drug Conjugates Market by Target Antigen

10.12 LAMEA Antibody Drug Conjugates Market by Drug

10.13 LAMEA Antibody Drug Conjugates Market by Linker Type

10.14 LAMEA Antibody Drug Conjugates Market by Application

11 Leading Company Profiles

11.1 Overview

11.2 AbbVie Inc. Company

11.2.1 Company Information

11.2.2 Company Overview

11.2.3 Company Financial Profile

11.2.4 Company Product Offerings

11.2.5 Company Recent Developments

11.3 Astellas Pharmaceuticals Company

11.3.1 Company Information

11.3.2 Company Overview

11.3.3 Company Financial Profile

11.3.4 Company Product Offerings

11.3.5 Company Recent Developments

11.4 Bayer Pharmaceuticals Company

11.4.1 Company Information

11.4.2 Company Overview

11.4.3 Company Financial Profile

11.4.4 Company Product Offerings

11.4.5 Company Recent Developments

11.5 Celldex Therapeutics Company

11.5.1 Company Information

11.5.2 Company Overview

11.5.3 Company Financial Profile

11.5.4 Company Recent Developments

11.6 Genentech Biotechnology Company

11.6.1 Company Information

11.6.2 Company Overview

11.6.3 Company Product Offerings

11.6.4 Company Recent Developments

11.7 ImmunoGen Biotechnology Company

11.7.1 Company Information

11.7.2 Company Overview

11.7.3 Company Financial Profile

11.7.4 Company Recent Developments

11.8 Immunomedics Inc. Company

11.8.1 Company Information

11.8.2 Company Overview

11.8.3 Company Financial Profile

11.8.4 Company Product Offerings

11.8.5 Company Recent Developments

11.9 Lonza Group AG Company

11.9.1 Company Information

11.9.2 Company Overview

11.9.3 Company Financial Profile

11.9.4 Company Product Offerings

11.9.5 Company Recent Developments

11.10 Mersana Therapeutics Inc. Company

11.10.1 Company Information

11.10.2 Company Overview

11.10.3 Company Financial Profile

11.10.4 Company Recent Developments

11.11 Takeda Pharmaceuticals Company Ltd.

11.11.1 Company Information

11.11.2 Company Overview

11.11.3 Company Financial Profile

11.11.4 Company Product Offerings

11.11.5 Company Recent Developments

11.12 Pfizer Inc Company

11.12.1 Company Information

11.12.2 Company Overview

11.12.3 Company Financial Profile

11.12.4 Company Product Offerings

11.12.5 Company Recent Developments

11.13 F. Hoffmann-La Roche Ltd Company

11.13.1 Company Information

11.13.2 Company Overview

11.13.3 Company Financial Profile

11.13.4 Company Product Offerings

11.13.5 Company Recent Developments

11.14 Lantheus Holdings Company

11.14.1 Company Information

11.14.2 Company Overview

11.14.3 Company Financial Profile

11.14.4 Company Product Offerings

11.14.5 Company Recent Developments

11.15 Seattle Genetics Company

11.15.1 Company Information

11.15.2 Company Overview

11.15.3 Company Financial Profile

11.15.4 Company Product Offerings

11.15.5 Company Recent Developments

11.16 Merck Group Chemicals Company

11.16.1 Company Information

11.16.2 Company Overview

11.16.3 Company Financial Profile

11.16.4 Company Product Offerings

11.16.5 Company Recent Developments

12 Antibody Drug Conjugate Product Pipeline Analysis

12.1 Manufacturer Strategies

12.2 1.Celldex Therapeutics.

12.3 Synthetic Modified Vaccines

12.3.1 Fully Synthetic Carbohydrate-Based Vaccines

12.3.2 A Synthetic Vaccine Against Meningococcal

12.3.3 Recent Development

13 Conclusion and Recommendations

13.1 List of Other Key Companies in the Market

13.2 List of Organizations Associated with Drugs

List of Figures

Figure 1.1 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %)

Figure 3.1 Antibody Drug Conjugate Action Mechanism Overview

Figure 5.1 Global Cancer Cases Breakdown by Gender and Type, 2019

Figure 6.1 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %)

Figure 6.2 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 6.3 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 6.4 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 6.5 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 6.6 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %)

Figure 6.7 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 6.8 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 6.9 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 6.10 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 6.11 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %)

Figure 6.12 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 6.13 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 6.14 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 6.15 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 6.16 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %)

Figure 6.17 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 6.18 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 6.19 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 6.20 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 6.21 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %)

Figure 6.22 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 6.23 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 6.24 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 6.25 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 6.26 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %)

Figure 6.27 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 6.28 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 6.29 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 6.30 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 6.31 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %)

Figure 6.32 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 6.33 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 6.34 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 6.35 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 7.1 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %)

Figure 7.2 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 7.3 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 7.4 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 7.5 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 7.6 North America Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %)

Figure 7.7 North America Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 7.8 North America Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 7.9 North America Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 7.10 North America Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 7.11 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %)

Figure 7.12 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 7.13 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 7.14 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 7.15 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 7.16 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %)

Figure 7.17 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 7.18 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 7.19 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 7.20 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 7.21 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %)

Figure 7.22 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 7.23 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 7.24 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 7.25 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 7.26 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %)

Figure 7.27 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 7.28 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 7.29 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 7.30 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 7.31 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %)

Figure 7.32 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 7.33 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 7.34 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 7.35 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 7.36 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %)

Figure 7.37 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 7.38 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 7.39 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 7.40 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 8.1 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %)

Figure 8.2 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 8.3 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 8.4 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 8.5 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 8.6 Europe Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %)

Figure 8.7 Europe Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 8.8 Europe Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 8.9 Europe Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 8.10 Europe Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 8.11 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %)

Figure 8.12 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 8.13 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 8.14 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 8.15 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 8.16 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %)

Figure 8.17 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 8.18 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 8.19 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 8.20 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 8.21 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %)

Figure 8.22 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 8.23 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 8.24 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 8.25 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 8.26 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %)

Figure 8.27 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 8.28 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 8.29 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 8.30 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 8.31 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %)

Figure 8.32 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 8.33 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 8.34 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 8.35 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 8.36 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %)

Figure 8.37 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 8.38 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 8.39 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 8.40 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 9.1 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %)

Figure 9.2 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 9.3 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 9.4 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 9.5 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 9.6 Asia-Pacific Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %)

Figure 9.7 Asia-Pacific Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 9.8 Asia-Pacific Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 9.9 Asia-Pacific Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 9.10 Asia-Pacific Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 9.11 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %)

Figure 9.12 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 9.13 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 9.14 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 9.15 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 9.16 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %)

Figure 9.17 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 9.18 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 9.19 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 9.20 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 9.21 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %)

Figure 9.22 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 9.23 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 9.24 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 9.25 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 9.26 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %)

Figure 9.27 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 9.28 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 9.29 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 9.30 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 9.31 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %)

Figure 9.32 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 9.33 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 9.34 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 9.35 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 9.36 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %)

Figure 9.37 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 9.38 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 9.39 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 9.40 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 10.1 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %)

Figure 10.2 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 10.3 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 10.4 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 10.5 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 10.6 LAMEA Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %)

Figure 10.7 LAMEA Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 10.8 LAMEA Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 10.9 LAMEA Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 10.10 LAMEA Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 10.11 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %)

Figure 10.12 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 10.13 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 10.14 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 10.15 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 10.16 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %)

Figure 10.17 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 10.18 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 10.19 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 10.20 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 10.21 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %)

Figure 10.22 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 10.23 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 10.24 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 10.25 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 10.26 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %)

Figure 10.27 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 10.28 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 10.29 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 10.30 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 10.31 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %)

Figure 10.32 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 10.33 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 10.34 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 10.35 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 10.36 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %)

Figure 10.37 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 10.38 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 10.39 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 10.40 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 11.1 AbbVie Inc: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.2 AbbVie Inc: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.3 AbbVie Inc: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.4 AbbVie Inc: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.5 Astellas Pharmaceuticals: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.6 Astellas Pharmaceuticals: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.7 Astellas Pharmaceuticals: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.8 Astellas Pharmaceuticals: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.9 Bayer Pharmaceuticals: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.10 Bayer Pharmaceuticals: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.11 Bayer Pharmaceuticals: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.12 Bayer Pharmaceuticals: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.13 Celldex Therapeutics: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.14 Celldex Therapeutics: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.15 Celldex Therapeutics: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.16 Celldex Therapeutics: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.17 ImmunoGen Biotechnology: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.18 ImmunoGen Biotechnology: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.19 ImmunoGen Biotechnology: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.20 ImmunoGen Biotechnology: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.21 Immunomedics Inc. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.22 Immunomedics Inc. Company: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.23 Immunomedics Inc. Company: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.24 Immunomedics Inc. Company: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.25 Lonza Group AG: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.26 Lonza Group AG.: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.27 Lonza Group AG.: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.28 Lonza Group AG.: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.29 Mersana Therapeutics Inc: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.30 Mersana Therapeutics Inc. Company: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.31 Mersana Therapeutics Inc. Company: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.32 Mersana Therapeutics Inc. Company: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.33 Takeda Pharmaceuticals: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.34 Takeda Pharmaceuticals: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.35 Takeda Pharmaceuticals: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.36 Takeda Pharmaceuticals: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.37 Pfizer Inc. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.38 Pfizer Inc. Company: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.39 Pfizer Inc. Company: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.40 Pfizer Inc. Company: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.41 La Roche Ltd. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.42 La Roche Ltd. Company: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.43 La Roche Ltd. Company: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.44 La Roche Ltd. Company: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.45 Lantheus Holdings Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.46 Lantheus Holdings Company: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.47 Lantheus Holdings Company: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.48 Lantheus Holdings Company: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.49 Seattle Genetics Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.50 Seattle Genetics Company: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.51 Seattle Genetics Company: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.52 Seattle Genetics Company: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.53 Merck Group Chemicals Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.54 Merck Group Chemicals Company: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.55 Merck Group Chemicals Company: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.56 Merck Group Chemicals Company: Company Net Income/Loss 2015-2019 (US$ Mn)

List of Tables

Table 1.1 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 2.1 Global Antibody Drug Conjugate Market Summary

Table 2.2 Global Antibody Drug Conjugate Market by Drugs and FDA Approval Details

Table 3.1 Types of Antibody Drug Conjugates Based on Type of Monoclonal Antibody

Table 4.1 Global Antibody Drug Conjugate Market by Drugs and FDA Approval Details

Table 4.2 60 ADC Projects Under Development In The Global Market

Table 5.1 Number of Cancer Cases in 2019

Table 6.1 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 6.2 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 6.3 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 6.4 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 6.5 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 6.6 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 6.7 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 6.8 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 6.9 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 6.10 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 6.11 Significant Antibody Drug Conjugate Linkers

Table 6.12 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 6.13 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 6.14 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 6.15 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 6.16 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 6.17 Significant Antibody Drug Conjugate Payloads

Table 6.18 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 6.19 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 6.20 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 6.21 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 6.22 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 6.23 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 6.24 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 6.25 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 6.26 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 6.27 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 6.28 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 6.29 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 6.30 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 6.31 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 6.32 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 6.33 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 6.34 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 6.35 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 6.36 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 6.37 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 7.1 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 7.2 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 7.3 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 7.4 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 7.5 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 7.6 US Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 7.7 US Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 7.8 US Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 7.9 US Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 7.10 US Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 7.11 Canada Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US$bilion, AGR %, CAGR %)

Table 7.12 Canada Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 7.13 Canada Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 7.14 Canada Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 7.15 Canada Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 7.16 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 7.17 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 7.18 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 7.19 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 7.20 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 7.21 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 7.22 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 7.23 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 7.24 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 7.25 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 7.26 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 7.27 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 7.28 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 7.29 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 7.30 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 7.31 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 7.32 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 7.33 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 7.34 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 7.35 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 7.36 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 7.37 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 7.38 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 7.39 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 7.40 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 7.41 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 7.42 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 7.43 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 7.44 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 7.45 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.1 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 8.2 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.3 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.4 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.5 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.6 Russia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 8.7 Russia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.8 Russia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.9 Russia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.10 Russia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.11 Germany Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 8.12 Germany Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.13 Germany Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.14 Germany Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.15 Germany Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.16 UK Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 8.17 UK Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.18 UK Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.19 UK Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.20 UK Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.21 France Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 8.22 France Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.23 France Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.24 France Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.25 France Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.26 Italy Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 8.27 Italy Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.28 Italy Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.29 Italy Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.30 Italy Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.31 Rest of Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 8.32 Rest of Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.33 Rest of Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.34 Rest of Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.35 Rest of Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.36 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 8.37 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.38 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.39 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.40 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.41 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 8.42 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 8.43 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 8.44 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 8.45 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 8.46 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 8.47 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 8.48 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 8.49 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 8.50 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 8.51 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 8.52 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 8.53 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 8.54 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 8.55 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 8.56 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 8.57 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 8.58 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 8.59 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 8.60 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 8.61 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 8.62 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.63 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.64 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.65 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.1 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 9.2 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.3 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.4 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.5 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.6 Japan Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 9.7 Japan Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.8 Japan Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.9 Japan Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.10 Japan Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.11 China Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 9.12 China Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.13 China Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.14 China Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.15 China Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.16 India Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 9.17 India Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.18 India Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.19 India Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.20 India Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.21 South Korea Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 9.22 South Korea Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.23 South Korea Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.24 South Korea Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.25 South Korea Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.26 Australia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 9.27 Australia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.28 Australia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.29 Australia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.30 Australia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.31 Rest of Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 9.32 Rest of Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.33 Rest of Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.34 Rest of Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.35 Rest of Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.36 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 9.37 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.38 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.39 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.40 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.41 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 9.42 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 9.43 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 9.44 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 9.45 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 9.46 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 9.47 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 9.48 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 9.49 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 9.50 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 9.51 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 9.52 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 9.53 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 9.54 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 9.55 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 9.56 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 9.57 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 9.58 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 9.59 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 9.60 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 9.61 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 9.62 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.63 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.64 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.65 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.1 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 10.2 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.3 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.4 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.5 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.6 Brazil Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 10.7 Brazil Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.8 Brazil Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.9 Brazil Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.10 Brazil Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.11 Saudi Arabia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 10.12 Saudi Arabia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.13 Saudi Arabia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.14 Saudi Arabia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.15 Saudi Arabia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.16 South Africa Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 10.17 South Africa Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.18 South Africa Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.19 South Africa Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.20 South Africa Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.21 Mexico Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 10.22 Mexico Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.23 Mexico Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.24 Mexico Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.25 Mexico Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.26 UAE Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 10.27 UAE Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.28 UAE Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.29 UAE Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.30 UAE Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.31 Rest of LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 10.32 Rest of LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.33 Rest of LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.34 Rest of LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.35 Rest of LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.36 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 10.37 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.38 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.39 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.40 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.41 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 10.42 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 10.43 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 10.44 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 10.45 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 10.46 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 10.47 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 10.48 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 10.49 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 10.50 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 10.51 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 10.52 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 10.53 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 10.54 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 10.55 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 10.56 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 10.57 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 10.58 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 10.59 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 10.60 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 10.61 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 10.62 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.63 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.64 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.65 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 11.1 AbbVie Inc: Company Information

Table 11.2 AbbVie Inc: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.3 AbbVie Inc: Company Product and Service Offerings

Table 11.4 AbbVie Inc: Company Recent Developments till Sept,2020

Table 11.5 Astellas Pharmaceuticals: Company Information

Table 11.6 Astellas Pharmaceuticals: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.7 Astellas Pharmaceuticals: Company Product and Service Offerings

Table 11.8 Astellas Pharmaceuticals: Company Recent Developments till Sept,2020

Table 11.9 Bayer Pharmaceuticals: Company Information

Table 11.10 Bayer Pharmaceuticals: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.11 Bayer Pharmaceuticals: Company Product and Service Offerings

Table 11.12 Bayer Pharmaceuticals: Company Recent Developments till Sept,2020

Table 11.13 Celldex Therapeutics: Company Information

Table 11.14 Celldex Therapeutics: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.15 Celldex Therapeutics: Company Recent Developments till Sept,2020

Table 11.16 Genentech Biotechnology: Company Information

Table 11.17 Genentech Biotechnology: Company Product and Service Offerings

Table 11.18 Genentech Biotechnology: Company Recent Developments till Sept,2020

Table 11.19 ImmunoGen Biotechnology: Company Information

Table 11.20 ImmunoGen Biotechnology. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.21 ImmunoGen Biotechnology: Company Recent Developments till Sept,2020

Table 11.22 Immunomedics Inc: Company Information

Table 11.23 Immunomedics Inc. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.24 Immunomedics Inc: Company Product and Service Offerings

Table 11.25 Immunomedics Inc: Company Recent Developments till Sept,2020

Table 11.26 Lonza Group AG: Company Information

Table 11.27 Lonza Group AG.: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.28 Lonza Group AG: Company Product and Service Offerings

Table 11.29 Lonza Group AG: Company Recent Developments till Sept,2020

Table 11.30 Mersana Therapeutics Inc: Company Information

Table 11.31 Mersana Therapeutics Inc. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.32 Mersana Therapeutics Inc: Company Recent Developments till Sept,2020

Table 11.33 Takeda Pharmaceuticals: Company Information

Table 11.34 Takeda Pharmaceuticals: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.35 Takeda Pharmaceuticals: Company Product and Service Offerings

Table 11.36 Takeda Pharmaceuticals: Company Recent Developments till Sept,2020

Table 11.37 Pfizer Inc: Company Information

Table 11.38 Pfizer Inc. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.39 Pfizer Inc: Company Product and Service Offerings

Table 11.40 Pfizer Inc: Company Recent Developments till Sept,2020

Table 11.41 La Roche Ltd: Company Information

Table 11.42 La Roche Ltd. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.43 La Roche Ltd: Company Product and Service Offerings

Table 11.44 La Roche Ltd: Company Recent Developments till Sept,2020

Table 11.45 Lantheus Holdings: Company Information

Table 11.46 Lantheus Holdings Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.47 Lantheus Holdings: Company Product and Service Offerings

Table 11.48 Lantheus Holdings: Company Recent Developments till Sept,2020

Table 11.49 Seattle Genetics: Company Information

Table 11.50 Seattle Genetics Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.51 Seattle Genetics: Company Product and Service Offerings

Table 11.52 Seattle Genetics: Company Recent Developments till Sept,2020

Table 11.53 Merck Group Chemicals: Company Information

Table 11.54 Merck Group Chemicals Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.55 Merck Group Chemicals: Company Product and Service Offerings

Table 11.56 Merck Group Chemical: Company Recent Developments till Sept,2020

Table 12.1 AbbVie Inc: Company Product Pipeline

Table 12.2 Astellas Pharmaceutics: Company Product Pipeline

Table 12.3 Bayer Pharmaceutics: Company Product Pipeline

Table 12.4 Celldex Therapeutics: Company Product Pipeline

Table 12.5 Genentech Biotechnology: Company Product Pipeline

Table 12.6 ImmunoGen Biotechnology: Company Product Pipeline

Table 12.7 Immunomedics Inc: Company Product Pipeline

Table 12.8 Mersana Therapeutics: Company Product Pipeline

Table 12.9 Takeda Pharmaceuticals: Company Product Pipeline

Table 12.10 Pfizer Inc: Company Product Pipeline

Table 12.11 Roche Ltd: Company Product Pipeline

Table 12.12 Lantheus Holdings: Company Product Pipeline

Table 12.13 Seattle Genetics: Company Product Pipeline

Table 12.14 Merck Group Chemicals: Company Product Pipeline

List of Companies Profiled in the report

AbbVie Inc.

Astellas Pharma Inc

Bayer Pharmaceuticals

Celldex Therapeutics, Inc.

Genentech Biotechnology

ImmunoGen Biotechnology

Immunomedics Inc

Lantheus Holdings, Inc.

Lonza Group AG (Lonza)

Merck KGaA

Mersana Therapeutics Inc.

Pfizer Inc. (Pfizer)

Roche Holding AG (Roche)

Seattle Genetics, Inc.

Takeda Pharmaceutical Company Limited

List of Other Companies Mentioned in the report

Abgenomics International Inc

Abzena Plc

ADC Bio

Adc Biotechnology Ltd.

Adc Therapeutics Sa

Affinicon Aps

Agensys Inc.

Agensys, Inc.

Ambrx Inc.

Amgen Inc.

Antikor

Antikor Biopharma Ltd.

Astellas Pharma U.S. Inc.

Astrazeneca Plc

Bayer Ag

Bionavigen

Bioss Antibodies

Biotecnol

Biotest Ag

Biotest Pharmaceuticals

Bristol Myers Squibb

Bristol-Myers Squibb Co.

Catalent Pharma Solutions

Celldex Therapeutics Inc

Celltrion

Centrose

Concortis Biotherapeutics

Creative Biolabs

Cytomx Therapeutics Inc

Daiichi Sankyo Co. Ltd

Dalton Pharma Services

Eli Lilly And Co

Esperance Pharmaceuticals Inc.

F. Hoffmann-La-Roche Ag (Roche)

Formation Biologics

Genmab A/S

Glaxosmithkline Plc

Heidelberg Pharma

Heidelberg Pharma Gmbh

Immunogen Inc.

Immunomedics Inc.

Lonza Pharma & Biotech

MabPlex

Mersana Therapeutics

Mersana Therapeutics Inc

Millennium Pharmaceuticals

Millennium Pharmaceuticals Inc. (Now Takeda Oncology)

MilliporeSigma

Minakem High Potent

Morphosys Ag

Nbe Therapeutics

Oxford Biotherapeutics

Pfizer Inc.

Philogen Spa

Pierre Fabre

Progenics Pharmaceuticals Inc.

Seattle Genetics Inc.

Sevion Therapeutics

Sorrento Therapeutics Inc

Sutro Biopharma Inc.

Synthon

Synthon Bv

Viventia Biotechnologies Inc.

Zhejiang Medicine Co. Ltd.

List of Associations

Australian Therapeutic Goods Administration (TGA)

Canadian International Pharmacy Association

Central Drugs Standard Control Organization (CDSCO) of India

China’s National Medical Products Administration (NMPA)

Contract Development and Manufacturing Organization (CDMO)

Drug Enforcement Administration (DEA)

Drug Information Association

International Confederation of Alcohol, Tobacco and other Drug (ATOD) Research Associations

International Conference of Drug Regulatory Authorities

International Drug Abuse Research Society (IDARS)

International Generic and Biosimilar medicines Association (IGBA)

International Narcotics Control Board (INCB)

International Narcotics Interdiction Association: INIA

International Society for Pharmaceutical Engineering

International Society of Drug Bulletins ISDB

Investigational New Drug application (IND)

Parenteral Drug Association

The International Dispensary Association Foundation

The International Drug Policy Consortium (IDPC)

The International Society for the Study of Drug Policy (ISSDP)

United States Food and Drug Administration (FDA)

Download sample pages

Complete the form below to download your free sample pages for Antibody Drug Conjugates Market Report 2021-2031

Download sample pages

Complete the form below to download your free sample pages for Antibody Drug Conjugates Market Report 2021-2031

Case studies

Need customized work?

Report overview

Methodology

Client testimonials

Pharmaceutical industry associations

American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Connect with us

Visiongain Pharma

Latest Pharma news

Visiongain Publishes Deep Frozen Packaging Logistics Market Report 2023-2033

The global Deep Frozen Packaging Logistics market was valued at US$21,088.3 million in 2022 and is projected to grow at a CAGR of 7.7% during the forecast period 2023-2033.

29 March 2023

READ

Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033

The global Automation in Biopharma Industry market was valued at US$1,784.1 million in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period 2023-2033.

20 March 2023

READ

Visiongain Publishes eClinical Solutions Market Report 2023-2033

The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.

17 March 2023

READ

Visiongain Publishes Therapeutic Respiratory Devices Market Report 2023-2033

The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.

15 March 2023

READ

Industries > Pharma > Antibody Drug Conjugates Market Report 2021-2031

Back to Pharma Reports

Antibody Drug Conjugates Market Report 2021-2031

Download sample pages

Related reports

Antibiotics Market Report 2021-2031

Lyophilisation in Pharmaceutical Market Report 2023-2033

Biological Drug API Manufacturing Services World Industry and Market Forecast to 2029

Deep Frozen Packaging Logistics Market Report 2022-2032

Antiviral Drugs Treatment Market Report 2021-2031

Drug Discovery Services Market Report 2022-2032

Global Next-Generation Antibody Therapies Market Forecast 2018-2028

Cell-Based Assays Market Report to 2030

Anti-Infective Agents Market Report 2021-2031

Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Download sample pages

Share

Connect with us

Latest Pharma news

Visiongain Publishes Deep Frozen Packaging Logistics Market Report 2023-2033

Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033

Visiongain Publishes eClinical Solutions Market Report 2023-2033

Visiongain Publishes Therapeutic Respiratory Devices Market Report 2023-2033

Our Clients